The role of adjuvant pharmacotherapy with liraglutide for patients with inadequate weight loss following bariatric surgery

• DOI: 10.1007/s00423-023-02805-8
• Publication Date: 2023-03-03T06:02:57Z
• Authors: James R. M. Colbo...; Oliver M. Fisher; Shirley Mo; Georgia S. Rigas; Michael L. Talbot
• Keywords: Tolerability; Pharmacotherapy

Abstract Purpose Despite the benefits of bariatric surgery for many patients, there are a proportion patients who do not achieve adequate weight loss. We evaluate role liraglutide as adjuvant pharmacotherapy in those respond poorly to loss surgery. Materials and Methods A non-controlled, prospective, open-label cohort study which participants prescribed following inadequate response The efficacy tolerability was measured through measurement BMI monitoring side effect profile. Results total 68 partial responders were included study, 2 lost follow-up. Overall 89.7% on liraglutide, with 22.1% showing good (>10% body loss). There 41 discontinued mainly due cost. Conclusion Liraglutide is efficacious achieving reasonably well tolerated have post-bariatric